B
Bull
Bull · 25%ADAP
$1.10
シナリオ価格
$0.055
-0.008 (-15.15%)終値時点
Loading chart…
- High
- 0.070
- Open
- 0.067
- VWAP
- 0.06
- Vol
- 50.78M
- Mkt Cap
- 250.66M
- Low
- 0.053
- Amount
- 3.01M
- EV/EBITDA, TTM
- 0.34
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Analyst Ratings (8)
+410.02% upside
Buy
6 Buy
1 Hold
1 Sell
Current: 0.05
安値
0.09
平均
0.28
高値
0.46
H.C. Wainwright
Neutral
—
2025-07-29
H.C. Wainwright
2025-07-29
目標株価
—
Neutral
Guggenheim
Neutral
—
2025-07-29
Guggenheim
2025-07-29
目標株価
—
Neutral
Mizuho
Neutral
$0.50
2025-06-25
Mizuho
2025-06-25
目標株価
$0.50
Neutral
Barclays
Underweight
$1
2025-05-14
Barclays
2025-05-14
目標株価
$1
Underweight
Wells Fargo
Equal Weight
$1
2025-05-14
Wells Fargo
2025-05-14
目標株価
$1
Equal Weight
バリュエーション指標
The current forward P/E ratio for Adaptimmune Therapeutics PLC (ADAP) is -0.71, compared to its 5-year average forward P/E of -2.71.
Alphio AI Price Scenarios for ADAP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ADAP
イベントタイムライン
ニュース
2.010-20SeekingAlphaAdaptimmune to be delisted from Nasdaq
2.010-09TipRanksWhat’s Driving the Pre-Market Surge of Adaptimmune Therapeutics Stock (ADAP) Today?
2.009-19Yahoo FinanceLeading Gainers in Premarket Trading
9.509-19BenzingaFedEx Shares Rise 5%; Check Out 20 Stocks Making Moves in Premarket Trading
2.009-19NASDAQ.COMEmerging Growth Stocks Experience Significant Gains in After-Hours Trading
ADAP FAQ — answered by Alphio AI
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
8 analysts cover ADAP: 6 rate it Buy, 1 Hold and 1 Sell. The average price target is 0.28.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。